Roche Diagnostics has announced the expansion of its digital pathology open environment with the integration of more than 20 advanced AI algorithms from eight new collaborators.
The Roche Digital Pathology Open Environment combines a wide range of AI-based pathology tools to help clinicians improve patient care and expand personalised healthcare.
Its new collaborators include Deep Bio, DiaDeep, Lunit, Mindpeak, Owkin, Qritive, Sonrai Analytics, and Stratipath.
Roche said the strategic collaborations will help pathologists and scientists in cancer research and diagnosis by leveraging advanced AI technology.
The integration is enabled through Roche’s navify Digital Pathology enterprise software, an enterprise software application designed for the pathologist’s workflow.
It will enable a suite of digital pathology tools that enhance biomarker testing for cancer research and improve patient outcomes through precision medicine.
The digital pathology solution now incorporates a wide range of AI-driven algorithms to enhance pathology insights for cancer patients through precision medicine and targeted treatments.
Roche Diagnostics pathology lab head Jill German said: “We are excited to welcome these new collaborators into our digital pathology ecosystem.
“By combining our leadership in tissue diagnostics with a broad offering of state-of-the-art AI technology, we aim to revolutionise cancer research, diagnostics and treatment, ultimately helping clinicians improve the lives of patients worldwide.”
Deep Bio integrated its algorithm for prostate cancer detection, grading, and tumour quantification, and DiaDeep for breast cancer biomarker quantification.
Lunit added its Lunit SCOPE PD-L1 22C3 for Tumour proportion score (TPS) analysis, and Mindpeak its tool for breast biomarkers and pan tumour PD-L1 for lung, gastric, oesophageal, bladder and breast cancers.
Owkin added its algorithm for microsatellite stability screening in colorectal cancer, and Qritive integrated its algorithm for screening and grading of prostate cancer, colon cancer and lymph nodes analysis.
Sonrai Analytics integrated its algorithm for determining microsatellite instability (MSI) status, and Stratipath for risk profiling of invasive breast cancer.
Lunit’s SCOPE PD-L1 22C3 TPS provides high-value insights and analysis of the PD-L1 TPS, a critical biomarker in cancer immunotherapy, and has been available for research since 2021.
Lunit CEO Brandon Suh said: “We’re thrilled to work together with Roche within its open digital pathology ecosystem, which we believe will create powerful synergies and represent a significant step toward making Lunit’s AI tools accessible globally.
“Today, we have made PD-L1 analysis available, and we look forward to sharing more of our tools on this platform in the future.
“By integrating our precise and reliable algorithms, we aim to accelerate the advancement of precision medicine, enhancing workflow efficiency and introducing new biomarkers for improved patient care.”
